Generation Bio Co. (GBIO)
After hours:
| Previous Close | 1.3300 |
| Open | 1.4300 |
| Bid | 1.6400 x 1000 |
| Ask | 1.7100 x 800 |
| Day's Range | 1.4101 - 1.6700 |
| 52 Week Range | 0.8600 - 7.3500 |
| Volume | |
| Avg. Volume | 666,901 |
| Market Cap | 109.689M |
| Beta (5Y Monthly) | 2.49 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.9700 |
| Earnings Date | Feb 21, 2024 - Feb 26, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.25 |
GuruFocus.comDirector Rowland Charles A Jr Acquires 342,960 Shares of Generation Bio Co (GBIO)
In a notable insider transaction, Rowland Charles A Jr, a director at Generation Bio Co, has significantly increased his stake in the company.
GlobeNewswireGeneration Bio Announces Strategic Reorganization to Extend Cash Runway for Development of ctLNP and iqDNA Platforms
Company to invest in highly selective cell-targeted lipid nanoparticle (ctLNP) delivery platform to develop wholly-owned programs for extrahepatic cell typesDevelopment of immune-quiet DNA (iqDNA) platform for lead hemophilia A program to continue Strategic reorganization will result in a 40% reduction of workforce Anticipated cost savings to extend cash runway into 2H 2027 CAMBRIDGE, Mass., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating ge
- GlobeNewswire
Generation Bio Reports Business Highlights and Third Quarter 2023 Financial Results
- Immune-quiet DNA evades innate immune sensors in both mice and non-human primates addressing a central challenge for non-viral DNA therapeutics - Proprietary cell-targeted LNP delivery system showed highly selective T cell transduction in humanized mouse model, demonstrating in vivo targeting for T cells and potentially for other extrahepatic tissues and cell types - Third quarter 2023 cash balance of $291.0 million expected to fund operations into 2026 CAMBRIDGE, Mass., Nov. 09, 2023 (GLOBE N
